Abstract

Despite recent improvements in local control of head and neck cancers (HNC), distant metastasis remains a major cause of death. Hence, further understanding of HNC biology, and in particular, the genes/pathways driving metastasis is essential to improve outcome. Quantitative reverse transcriptase PCR (qRT-PCR) was used to measure the expression of miR-375 and metadherin (MTDH) in HNC patient samples. Targets of miR-375 were confirmed using qRT-PCR, Western blot analysis, and luciferase assays. Phenotypic effects of miR-375 reexpression and MTDH knockdown were assessed using viability (MTS), clonogenic survival, cell migration/invasion, as well as in vivo tumor formation assays. The prognostic significance of miR-375 or MTDH in nasopharyngeal carcinoma (NPC) was determined by comparing low versus high expression groups. MiR-375 expression was significantly reduced (P = 0.01), and conversely, MTDH was significantly increased (P = 0.0001) in NPC samples. qRT-PCR, Western blots, and luciferase assays corroborated MTDH as a target of miR-375. Reexpression of miR-375 and siRNA knockdown of MTDH both decreased cell viability and clonogenic survival, cell migration/invasion, as well as in vivo tumor formation. NPC patients whose tumors expressed high levels of MTDH experienced significantly lower survival and, in particular, higher distant relapse rates (5-year distant relapse rates: 26% vs. 5%; P = 0.005). Dysregulation of miR-375 and MTDH may represent an important oncogenic pathway driving human HNC progression, particularly distant metastases, which is now emerging as a major cause of death for HNC patients. Hence, targeting this pathway could potentially be a novel therapeutic strategy by which HNC patient outcome could be improved.

Highlights

  • Head and neck squamous cell carcinomas (HNSCC) constitute the fifth most common malignancy worldwide [1]

  • Nasopharyngeal carcinoma (NPC) patients whose tumors expressed high levels of MTDH experienced significantly lower survival and, in particular, higher distant relapse rates (5-year distant relapse rates: 26% vs. 5%; P 1⁄4 0.005)

  • Dysregulation of miR-375 and MTDH may represent an important oncogenic pathway driving human head and neck cancers (HNC) progression, distant metastases, which is emerging as a major cause of death for HNC patients

Read more

Summary

Introduction

Head and neck squamous cell carcinomas (HNSCC) constitute the fifth most common malignancy worldwide [1]. Patients with locally advanced HNSCC have 5-year overall survival (OS) rates hovering around 30% to 45%. Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/). (2), underscoring a considerable opportunity for improving outcome. Nasopharyngeal carcinoma (NPC) is another malignancy of the head and neck region; NPCs are distinct from other head and neck cancers (HNC) due to their unique etiologic, clinical/biological, and epidemiologic characteristics. Advanced NPC patients have a 5-year OS rate of approximately 70% [3], showing a need for improvement. It is imperative to acquire a deeper understanding of HNC biology to guide the development and evaluation of novel therapies, to improve patient outcome

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call